| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -23.9 | -18.1 |
| EPS (diluted, $ a share) | $-3.47 | $-616.86 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ETRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Electra Therapeutics, Inc.: key numbers
- Share price
- $8.31Close, Nov 16
- Market cap
- $522M
- Shares outstanding
- 62.87MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Electra Therapeutics, Inc.
All →Electra Therapeutics Financial Results
Electra Therapeutics reported third quarter 2026 financial results and provided updates on its SIRP-targeting portfolio, including the advancement of ipsoprubart in a global registrational program for sHLH. The company recently completed a $350 million IPO to fund its clinical pipeline, with several data readouts and enrollment milestones expected throughout 2027.
“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion. Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”
Kathy Dong, PharmD, MBA, President and Chief Executive Officer
Electra Therapeutics Insider Carl L. Gordon Buys $745K of Stock
Carl L. Gordon bought 92,116 shares of Electra Therapeutics, Inc. at $7.85 to $8.45 a share (average $8.08) in 6 transactions, worth $745K in total between Nov 6, 2026 and Nov 10, 2026. Shares held after the trade: 2,194,579 (+0.1%).
- Value
- $745K
- Shares
- 92,116
- Average price
- $8.08
- Holding change
- +0.1%
- Trade date
- Nov 6, 2026 to Nov 10, 2026
Electra Therapeutics Insider Orbimed Advisors LLC Buys $745K of Stock
Orbimed Advisors LLC bought 92,116 shares of Electra Therapeutics, Inc. at $7.85 to $8.45 a share (average $8.08) in 6 transactions, worth $745K in total between Nov 6, 2026 and Nov 10, 2026. Shares held after the trade: 2,194,579 (+0.1%).
- Value
- $745K
- Shares
- 92,116
- Average price
- $8.08
- Holding change
- +0.1%
- Trade date
- Nov 6, 2026 to Nov 10, 2026
Electra Therapeutics Insider Carl L. Gordon Buys $3.61M of Stock
Carl L. Gordon bought 472,571 shares of Electra Therapeutics, Inc. at $7.07 to $7.88 a share (average $7.63) in 10 transactions, worth $3.61M in total between Nov 3, 2026 and Nov 5, 2026. Shares held after the trade: 2,136,979 (+6.2%).
- Value
- $3.61M
- Shares
- 472,571
- Average price
- $7.63
- Holding change
- +6.2%
- Trade date
- Nov 3, 2026 to Nov 5, 2026
Electra Therapeutics Insider Orbimed Advisors LLC Buys $3.61M of Stock
Orbimed Advisors LLC bought 472,571 shares of Electra Therapeutics, Inc. at $7.07 to $7.88 a share (average $7.63) in 10 transactions, worth $3.61M in total between Nov 3, 2026 and Nov 5, 2026. Shares held after the trade: 2,136,979 (+6.2%).
- Value
- $3.61M
- Shares
- 472,571
- Average price
- $7.63
- Holding change
- +6.2%
- Trade date
- Nov 3, 2026 to Nov 5, 2026
Electra Therapeutics Capital Raise of $350M
Electra Therapeutics closed its initial public offering (IPO) of 23,333,334 shares of common stock at a price of $15.00 per share, generating gross proceeds of approximately $350.0 million. In connection with the closing, the company also filed its amended and restated certificate of incorporation and bylaws.
- Value
- $350M